Rouen, France, December 14, 2020 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has appointed Chantal Le Chat as an independent member of the Strategic Committee.
Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including Global GM. Her duties as an independent member of the Strategic Committee will include supporting the governance of Robocath. She will use her extensive knowledge of imaging systems to analyze strategic opportunities for promoting interoperability of equipments used in cath labs, in particular compatibility with R-One™, the first robotic platform, as well as future robotic generations.
Philippe Bencteux, President and founder of Robocath, said: “I’m honored that a leader in medical interventional imaging such as Chantal shares our vision for robot-controlled vascular operations. I’m excited to welcome her to the Strategic Committee. Her impressive experience will be key in advancing future developments at Robocath.”
Lucien Goffart, CEO of Robocath, added: “I’m also delighted that we’ve been able to boost our Strategic Committee by appointing Chantal. The sector is currently seeing significant changes, with the advent of new technologies that promise significant added value. Robotics makes up a key part of this trend, and new robotic projects will need to predict and embrace changes in the sector in order to ensure that they remain relevant in the market over the medium and long term. Chantal’s experience, working for a leading imaging company, will help us to quickly identify which technological development opportunities to focus on in order to speed up implementation and lock in growth.”
Chantal Le Chat, Independent Strategic Committee Member of Robocath, said: “I’m happy to be joining the Strategic Committee at Robocath. I’ve been following the company and its progress for a number of years, and I’m especially impressed with the strides it has taken since being awarded CE marking for its first robot in February 2019. The company is now right at the heart of a revolution in interventional medicine, which comes with a number of benefits for physicians, such as greater comfort and complete protection from X-rays, while the level of precision a robot can deliver is a boon for patients. Robocath’s commercial expansion is highly promising and, with its integration in the cath lab, the product should see significant growth. I’m looking forward to using my experience to help the company achieve its goals.”
Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRays tubes as well as the Vascular organization based in Buc (France) or Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming in 2002 the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence and profitable growth. In 2005, Chantal was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation as well as introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-14, she expanded her role to cover also the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the “Ecole Supérieure de Physique et Chimie Industrielles” (ESPCI) and a Master in Medical Instrumentations, Paris France – 1985.
|Morgane Le Mellay|
|FR/UK: +33 (0)6 34 40 91 25|
|Juliette Schmitt-dos Santos / Amanda Bown|
|email@example.com / firstname.lastname@example.org|
|UK: + 44 1273 675 100 / US: + 1 617 202 4491|